NSTEMI / unstable angina - early management
ACS pathway · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Non-ST-elevation acute coronary syndrome managed by risk-stratified pathway: antiplatelet and anticoagulation, anti-ischaemic therapy and early invasive angiography for higher-risk patients (e.g. GRACE), with urgent intervention for ongoing ischaemia or instability.
Assessment
Investigations
- Serial ECGs and high-sensitivity troponin
- GRACE risk score; identify ongoing ischaemia/instability
- Bloods, echo as needed
Management
- Aspirin 300 mg; add a second antiplatelet per pathway/local protocol
- Anticoagulation (e.g. fondaparinux) unless going to immediate angiography
- Anti-ischaemic therapy: nitrates, beta-blocker (if no contraindication)
- Early invasive angiography - within 24 h if high risk (GRACE >140/ongoing ischaemia), within 72 h otherwise
- Immediate angiography for refractory ischaemia, instability or dynamic changes (treat as STEMI-equivalent)
- Oxygen only if SpO2 <94%; analgesia
- CCU/monitored bed; secondary prevention
Drugs & doses
Aspirin 300 mg + 2nd antiplatelet
Fondaparinux (anticoagulation)
Nitrate / beta-blocker
Early angiography (risk-based)
Disposition
CCU/cardiology.
Risk-stratify NSTEMI with GRACE - high-risk or ongoing ischaemia goes to angiography within 24 hours, and refractory ischaemia is a STEMI-equivalent.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.